Abstract:BackgroundThe standard dose of rituximab used in rheumatoid arthritis (RA) is 1000 mg but recent studies have shown that low dose (500 mg) is also effective. Efficacy of low dose rituximab in rheumatoid arthritis (RA) refractory to first-line non-biologic Disease Modifying Anti Rheumatic Drugs (DMARDs), compared to leflunomide is unknown. In a tertiary care referral setting, we conducted a randomized, double blind controlled clinical trial comparing the efficacy and safety of low-dose rituximab-methotrexate combination with leflunomide-methotrexate combination.MethodsPatients on methotrexate (10-20 mg/week) with a Disease Activity Score (DAS) > 3.2 were randomly assigned to rituximab (500 mg on days 1 and 15) or leflunomide (10-20 mg/day). The primary end-point was ACR20 at 24 weeks. Sample of 40 had 70% power to detect a 30% difference. ACR50, ACR70, DAS, EULAR good response, CD3 + (T cell), CD19 + (B cell) and CD19 + CD27+ (memory B cell) counts, tetanus and pneumococcal antibody levels were secondary end points.ResultsBaseline characteristics were comparable in the two groups. At week 24, ACR20 was 85% vs 84% (p = 0.93), ACR50 was 60% vs. 64% (p = 0.79) and ACR70 was 35% vs 32% (P = 0.84), in rituximab and in leflunomide groups respectively. Serious adverse events were similar.With rituximab there was significant reduction in B cells (p < 0.001), memory B cells (p < 0.001) and pneumococcal antibody levels (P < 0.05) without significant changes in T cells (p = 0.835) and tetanus antibody levels (p = 0.424) at 24 weeks. With leflunomide, significant reduction in memory B cells (p < 0.01) and pneumococcal antibody levels (p < 0.01) occurred without significant changes in B cells (P > 0.05), T cells (P > 0.05) or tetanus antibody levels (P > 0.05).ConclusionsLeflunomide-methotrexate combination is as efficacious as low-dose rituximab-methotrexate combination at 24 weeks, in RA patient’s refractory to initial DMARDs. The high responses seen in both groups have favorable cost implications for patients in developing countries. Changes in immune parameters with leflunomide are novel and need further characterization.Trial registrationThe trial was registered with the Sri Lanka Clinical Trials Registry (SLCTR), a publicly accessible primary registry linked to the registry network of the International Clinical Trials Registry Platform of the WHO (WHO-ICTRP) (registration number: SLCTR/2008/008 dated 16th May 2008).

A Multicenter, Double-Blind, and Randomized Controlled Trial of Leflunomide in Rheumatoid Arthritis

The efficacy and safety of iguratimod or leflunomide combined with methotrexate in treating active rheumatoid arthritis (TRANMOD): a multicenter, randomized, double-blinded, double dummy and controlled clinical trial

Randomized double - blind controlled clinical trial of leflunomide in the treatment of rheumatoid arthritis

Efficacy and Safety of Weekly Leflunomide for the Treatment of Early Rheumatoid Arthritis: a Randomized, Multi‐center Study

Leflunomide, a New Disease-Modifying Drug for Treating Active Rheumatoid Arthritis in Methotrexate-Controlled Phase II Clinical Trial.

Observation of the Efficacy of Leflunomide and Methotrexate in the Treatment of Rheumatoid Arthritis

Leflunomide for Rheumatoid Arthritis in Phase Ⅱ Clinical Study

Evidence-based Treatment of a Patient with Rheumatoid Arthritis with Leflunomide

Clinical trial of Leflunomide in active ankylosing spondylitis

The Efficacy And Safety Of Leflunomide For The Treatment Of Lupus Nephritis In Chinese Patients: Systematic Review And Meta-Analysis

The efficacy of leflunomide and methotrexate combined with low-dose prednisone in the treatment of rheumatoid arthritis

Leflunomide Versus Cyclophosphamide in the Induction Treatment of Proliferative Lupus Nephritis in Chinese Patients: a Randomized Trial.

Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial

Treatment of Active Ankylosing Spondylitis with Leflunomide and Methotrexate : a Prospective Controlled Clinical Trial

Effect of leflunomide on Th1/Th2 balance in the peripheral blood and joint function of patients with rheumatoid arthritis

Effect of leflunomide on senile rheumatoid arthritis

Clinical Analysis of Chinese Patients With Rheumatoid Arthritis Treated With Leflunomide and Methotrexate Combined With Different Dosages of Glucocorticoid

Efficacy of low-dose leflunomide in lupus nephritis: A multi-center prospective study

Leflunomide in Pakistani Patients with Rheumatoid Arthritis: Prospective Study in Daily Rheumatology Practice.

The Efficacy and Safety of the Combination of Total Glucosides of Peony and Leflunomide for the Treatment of Rheumatoid Arthritis: A Systemic Review and Meta-Analysis.

Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials